8-K current report · filed Nov 5, 2026

Alnylam Pharmaceuticals (ALNY) 8-K Current Report: November 5, 2026

Item 5.02Item 8.01ALNY overview

Short answer

Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). Chief Commercialization Officer Tolga Tanguler departing in December 2026.

Alnylam Pharmaceuticals 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Chief Commercialization Officer Tolga Tanguler departing in December 2026
  • Planned written separation agreement, terms not yet disclosed
  • Leadership transition risk for Alnylam’s commercial execution and product launches

Item 8.01 · Other Events

  • $1.0 billion share repurchase authorization, signaling capital return and potential support for ALNY’s stock
  • Approximately $500 million targeted for repurchase by end-2026, with the balance planned during 2027
  • No expiration date or purchase obligation, leaving execution dependent on liquidity, market price and investment opportunities
  • Program may be modified, suspended or discontinued without prior notice, limiting certainty around actual share reduction

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Alnylam Pharmaceuticals 8-K filings

Get the next ALNY 8-K as it lands

Follow ALNY for push alerts, or ask the research agent what this filing means.